AR098663A1 - Anticuerpos multifuncionales que se unen a egfr y met - Google Patents

Anticuerpos multifuncionales que se unen a egfr y met

Info

Publication number
AR098663A1
AR098663A1 ARP140104569A ARP140104569A AR098663A1 AR 098663 A1 AR098663 A1 AR 098663A1 AR P140104569 A ARP140104569 A AR P140104569A AR P140104569 A ARP140104569 A AR P140104569A AR 098663 A1 AR098663 A1 AR 098663A1
Authority
AR
Argentina
Prior art keywords
seq
scfv
egfr
met
amino acid
Prior art date
Application number
ARP140104569A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR098663A1 publication Critical patent/AR098663A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente se refiere a anticuerpos multifuncionales, y/o tales fragmentos de unión al antígeno, que se unen a, e inhiben la actividad de, tanto el receptor del factor de crecimiento epidermal humano (EGFR) y MET (receptor humano para el factor de crecimiento del hepatocito humano (HGF)), y que son efectivos en el tratamiento de cánceres y otras enfermedades, trastornos o condiciones donde la patogénesis es mediada por EGFR y MET. Reivindicación 1: Un anticuerpo multifuncional caracterizado porque comprende: (a) un anticuerpo que se une a MET y comprende: i) una cadena pesada que comprende CDRs de cadena pesada HCDR1, HCDR2, y HCDR3 que consisten de las secuencias de aminoácido de GYTFTDYYMH (SEC ID Nº 11), RVNPNRRGTTYNQKFEG (SEC ID Nº 12), y ARANWLDY (SEC ID Nº 13), respectivamente; y ii) una cadena ligera que comprende las CDRs de cadena ligera LCDR1, LCDR2 y LCDR3 que consisten de las secuencias de aminoácido de SVSSSVSSIYLH (SEC ID Nº 14), YSTSNLAS (SEC ID Nº 15) y QVYSGYPLT (SEC ID Nº 16), respectivamente; y (b) un polipéptido scFv que se une al EGFR y comprende: i) un dominio de HCVR que comprende CDRs scFv scFv-HCDR1, scFv-HCDR2, y scFv-HCDR3 que consisten de; las secuencias de aminoácido GFSLTNYGVH (SEC ID Nº 1), VIX¹SGGNTDYNTPFX²G (SEC ID Nº 9), en donde X¹ es Y o W, X² es K o T, y ARALDYYDYDFAY (SEC ID Nº 3) respectivamente; y ii) un dominio LCVR que comprende CDRs scFv scFv-LCDR1, scFv-LCDR2, y scFv-LCDR3 que consisten de las secuencias de aminoácido RASYSIGTNIH (SEC ID Nº 4), X¹YAX²X³SIS (SEC ID Nº 10), en donde X¹ es R o Y, X² es K o S, y X³ es E o R, y QQNNAWPTT (SEC ID Nº 6) respectivamente.
ARP140104569A 2013-12-23 2014-12-09 Anticuerpos multifuncionales que se unen a egfr y met AR098663A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361920097P 2013-12-23 2013-12-23

Publications (1)

Publication Number Publication Date
AR098663A1 true AR098663A1 (es) 2016-06-01

Family

ID=52396806

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140104569A AR098663A1 (es) 2013-12-23 2014-12-09 Anticuerpos multifuncionales que se unen a egfr y met

Country Status (9)

Country Link
US (1) US9328173B2 (es)
EP (1) EP3087097B1 (es)
JP (1) JP2017504608A (es)
CN (1) CN105829345B (es)
AR (1) AR098663A1 (es)
CA (1) CA2930162A1 (es)
ES (1) ES2699584T3 (es)
TW (1) TW201609805A (es)
WO (1) WO2015100104A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201800000534A1 (it) * 2018-01-03 2019-07-03 Procedimenti per la promozione della crescita cellulare degli isolotti pancreatici.
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
CN110028584B (zh) * 2018-01-12 2021-04-06 北京科昕生物科技有限公司 针对egfr蛋白和met蛋白的双特异性抗体
US11266624B2 (en) * 2018-04-03 2022-03-08 Texas Tech University System CRM1 inhibitors reduce primary and acquired resistance of EGFR inhibitors in lung cancer cells
CA3128519A1 (en) 2019-02-21 2020-08-27 Regeneron Pharmaceuticals, Inc. Methods of treating ocular cancer using anti-met antibodies and bispecific antigen binding molecules that bind met
KR20220063185A (ko) 2019-09-16 2022-05-17 리제너론 파마슈티칼스 인코포레이티드 면역-pet 영상화를 위한 방사성 표지된 met 결합 단백질
WO2024002235A1 (en) * 2022-06-29 2024-01-04 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-egfr/met antibodies and uses thereof
WO2024036333A2 (en) * 2022-08-12 2024-02-15 Epibiologics, Inc. Degradation of egfr using a bispecific binding agent
WO2024050466A1 (en) 2022-09-01 2024-03-07 Regeneron Pharmaceuticals, Inc. Methods of treating non-small cell lung cancer using mesenchymal epithelial transition factor (met)-targeted agents

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
SI2857516T1 (sl) 2000-04-11 2017-09-29 Genentech, Inc. Multivalentna protitelesa in njihove uporabe
RU2433831C2 (ru) 2004-05-05 2011-11-20 Мерримак Фармасьютикалз, Инк. Биспецифические связывающие агенты для модулирования биологической активности
JP2009515878A (ja) * 2005-11-12 2009-04-16 イーライ リリー アンド カンパニー 抗ｅｇｆｒ抗体
EP2615115A3 (en) 2007-11-30 2014-01-08 Glaxo Group Limited Antigen-binding constructs
CN102014913A (zh) 2008-03-06 2011-04-13 健泰科生物技术公司 C-met和egfr拮抗剂的联合疗法
PE20091827A1 (es) 2008-04-11 2009-11-20 Galaxy Biotech Llc Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancer
US20110229469A1 (en) 2008-10-01 2011-09-22 Ludwig Institute For Cancer Research Methods for the treatment of cancer
PA8849001A1 (es) * 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
JP2012515540A (ja) 2009-01-26 2012-07-12 ゲンマブ エー／エス 抗体混合物を産生するための方法
KR20110126748A (ko) * 2009-04-07 2011-11-23 로슈 글리카트 아게 이중특이적 항-ｅｒｂｂ-1/항-ｃ-ｍｅｔ 항체
CN102448985B (zh) 2009-05-27 2015-08-05 霍夫曼-拉罗奇有限公司 三或四特异性抗体
WO2011059762A1 (en) * 2009-10-28 2011-05-19 Abbott Biotherapeutics Corp. Anti-egfr antibodies and their uses
TWI586806B (zh) * 2010-04-23 2017-06-11 建南德克公司 異多聚體蛋白質之製造
JP2015527869A (ja) * 2011-08-26 2015-09-24 メリマック ファーマシューティカルズ インコーポレーティッド タンデムＦｃ二重特異性抗体
JP2014530201A (ja) * 2011-09-20 2014-11-17 イーライ リリー アンド カンパニー 抗ｃ−Ｍｅｔ抗体
NZ630020A (en) * 2012-03-08 2016-08-26 Halozyme Inc Conditionally active anti-epidermal growth factor receptor antibodies and methods of use thereof
KR102029137B1 (ko) 2013-03-27 2019-10-08 삼성전자주식회사 EGFR 길항제 및 항 c-Met 항체를 포함하는 병용 투여용 약학 조성물
KR102074421B1 (ko) 2013-03-29 2020-02-10 삼성전자주식회사 항 c-Met/항 EGFR 이중 특이 항체

Also Published As

Publication number Publication date
CA2930162A1 (en) 2015-07-02
JP2017504608A (ja) 2017-02-09
TW201609805A (zh) 2016-03-16
EP3087097B1 (en) 2018-11-14
WO2015100104A1 (en) 2015-07-02
CN105829345A (zh) 2016-08-03
EP3087097A1 (en) 2016-11-02
US9328173B2 (en) 2016-05-03
US20150175708A1 (en) 2015-06-25
CN105829345B (zh) 2019-12-10
ES2699584T3 (es) 2019-02-11

Similar Documents

Publication Publication Date Title
AR098663A1 (es) Anticuerpos multifuncionales que se unen a egfr y met
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
PH12021550023A1 (en) Humanized anti-tau antibodies
PE20180604A1 (es) Anticuerpos pd-l1 (que se unen al ligando 1 de muerte celular programada 1 humana)
AR110203A1 (es) Anticuerpos anti-tim-3 para combinación con anticuerpos anti-pd-1
PE20181326A1 (es) Anticuerpos que se unen especificamente a pd-1 y sus usos
AR103713A1 (es) Anticuerpos contra tau y sus usos
PE20190630A1 (es) Anticuerpos de anti-tim-3
AR126019A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
HRP20171992T1 (hr) Protutijela protiv cgrp
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
AR102239A1 (es) Anticuerpos anti-ox40 humanizados y sus usos
PE20181090A1 (es) Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
PE20210180A1 (es) Anticuerpos anti-cd33, anticuerpos biespecificos anti-cd33/anti-cd3 y usos de estos
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
PE20221580A1 (es) Anticuerpos terapeuticos y sus usos
PE20212088A1 (es) Anticuerpos anti-tau y uso de los mismos
NZ628943A (en) Human antibodies to clostridium difficile toxins
JP2013542194A5 (es)
NZ706377A (en) Il-6 antagonists and uses thereof
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
PE20191079A1 (es) Inmunoglobulinas y usos de estas
AR109715A1 (es) Anticuerpos anti-cd27

Legal Events

Date Code Title Description
FB Suspension of granting procedure